Journal article
A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer
Abstract
BACKGROUND: The downstream signaling pathways of the epidermal growth factor receptor might influence radiation resistance. Data from preclinical work support the hypothesis that erlotinib concurrent with radiation therapy (RT) might increase cancer cell killing. The present trial was designed to examine the efficacy and toxicity of combined erlotinib and palliative chest thoracic RT in non-small-cell lung cancer (NSCLC).
MATERIALS AND METHODS: …
Authors
Swaminath A; Wright JR; Tsakiridis TK; Ung YC; Pond GR; Sur R; Corbett TB; Okawara G; Levine MN
Journal
Clinical Lung Cancer, Vol. 17, No. 2, pp. 142–149
Publisher
Elsevier
Publication Date
March 2016
DOI
10.1016/j.cllc.2015.09.008
ISSN
1525-7304